Capital Cell

MgShell specializes in developing innovative intraocular devices aimed at treating age-related macular degeneration and other ocular diseases. The company has created a biodegradable drug delivery device that mimics existing clinical treatment methods, allowing for a single injection that autonomously releases therapeutic drug doses at predetermined intervals. This approach significantly reduces the need for frequent intravitreal injections, thereby alleviating the associated therapeutic burdens and enhancing patient adherence to treatment. By minimizing the number of injections required, MgShell's technology not only simplifies the management of maculopathy and retinal diseases but also helps mitigate the risk of vision loss in patients.

MSInsight is a bioinformatics startup that specializes in developing diagnostic and treatment response prediction solutions for cancers with Microsatellite Instability (MSI). The company's core offering revolves around identifying and analyzing diagnostic and prognostic biomarkers of treatment response in MSI tumors. By leveraging next-generation sequencing data, MSInsight's platform provides actionable insights on MSI status, a critical biomarker for cancer treatment, enabling healthcare professionals to make informed decisions about patient care, particularly in relation to immunotherapy options, and ultimately improve patient outcomes.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Affirma Biotech is a biotechnology research company focused on developing host-directed drugs to treat chronic and severe infectious diseases. By employing host-directed therapy strategies, the company aims to disrupt the host cell factors essential for the replication and persistence of pathogens. Affirma specializes in discovering and developing immunotherapeutic drugs that are orally available, targeting both severe infections and cancer. Through its comprehensive approach, the company manages the entire pharmaceutical development process, facilitating access to innovative therapeutic tools that address urgent global health challenges related to viral infections.

MediQuo is a healthcare application that connects patients with medical professionals through a chat-based platform, enabling various health interactions without the need for in-person visits. It addresses the inefficiencies of traditional healthcare by facilitating remote consultations, thereby reducing unnecessary medical visits. The app is designed to be compliant with GDPR, ensuring the privacy and security of health data while allowing professionals to manage patient information and communications effectively. Users can engage in text, audio, or video consultations, share medical documents, and access a network of healthcare information and professional services. With over one million consultations conducted and 600,000 downloads, MediQuo has established itself as a leading health app in Spain and Latin America, boasting a Google Play rating of 4.6 based on 6,000 reviews.

Loop Dx is developing point-of-care diagnostics for faster detection of sepsis to reduce sepsis mortality, patient side effects, and antibiotic resistance due to unnecessary provided antibiotics. We want to facilitate healthcare providers the tools they need for faster sepsis identification saving lives and optimizing sepsis management.

Exheus tells everything that you need to know to take maximum care of yourself and avoid risks to your health, exheus is much more than a DNA test that only indicates which genes you have.

Oncostellae SL, founded in 2013 and based in Ourense, Spain, specializes in the development of small molecule drugs aimed at treating cancer. The company was established by a group of researchers with expertise in chemistry, biochemistry, and pharmacology, all of whom have experience in advancing clinical drug candidates through to phase II trials. Oncostellae's strategy focuses on creating pharmaceutical research programs that target validated cancer mechanisms, such as nuclear receptors and kinases. By maintaining a streamlined internal team that emphasizes project management, medicinal chemistry, and in vitro pharmacology, the company optimizes its operations. Other aspects of the research and development process, including in vivo pharmacology, toxicology, and clinical trials, are outsourced to specialized providers. Oncostellae aims to license its clinical drug candidates, including associated intellectual property and comprehensive data packages, to established pharmaceutical or biotechnology companies.

Inrobics is a company that focuses on enhancing rehabilitation through the integration of artificial intelligence and social robots. Their cloud-based platform is designed to assist individuals with functional or neurological limitations, offering personalized treatment options that can be utilized in rehabilitation centers or within the comfort of the patient's home. Inrobics' technology aims to improve the quality of rehabilitation by addressing the specific needs of clients affected by brain damage, neurodevelopmental disorders, or related conditions. Through their innovative approach, Inrobics provides not only rehabilitation treatments but also support and education, fostering overall well-being for those in need.

Mowoot is a company that specializes in developing non-pharmacological and non-invasive solutions for individuals suffering from chronic constipation. It offers a wearable medical device that delivers an automatic, colon-specific massage, mimicking the manual abdominal massage typically performed by healthcare professionals. Utilizing advanced pneumatic technology, Mowoot's device aims to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Founded in 2014 and based in Barcelona, Spain, Mowoot emerged from the MOEBIO dHEALTH program, which draws inspiration from innovative design and business methodologies. The company's mission is to enhance the quality of life for those affected by chronic constipation through its unique and effective approach.

Kintsugi Therapeutics is a preclinical biopharmaceutical company focused on developing therapies for liver conditions, including Non-Alcoholic Steatohepatitis (NASH). The company specializes in creating endoplasmic reticulum (ER) stress inhibitors aimed at addressing liver diseases and other related health issues. By targeting the regulation of ER stress, Kintsugi Therapeutics seeks to provide effective treatment options that can enhance the quality of life for patients suffering from these conditions.

FrontWave Imaging specializes in developing advanced 3D ultrasound supercomputing software aimed at enhancing breast cancer diagnostics. The company provides a medical device that generates high-quality three-dimensional ultrasound images of the breast, facilitating improved monitoring of breast tumors. Its technology encompasses a comprehensive service offering, including data transfer to the cloud, image reconstruction, and visualization and analysis through an intuitive interface. This innovative approach allows medical professionals to assess breast health effectively while minimizing patient exposure to harmful ionizing radiation.

Corify Care SL is a medical technology company based in Madrid, Spain, focused on improving the treatment of atrial fibrillation through its innovative non-invasive electrocardiographic imaging device, ACORYS. This device allows healthcare professionals to visualize the electrical activity of the heart in real time without the need for invasive procedures, such as catheters or complex imaging techniques like MRI or CT scans. By addressing the limitations of existing solutions, ACORYS enhances the clinical management of cardiac arrhythmias, enabling accurate mapping and identification of optimal treatment strategies for patients. The technology has the potential to benefit over 10 million atrial fibrillation patients in Europe alone. Established in 2019, Corify Care is backed by leading experts in cardiac arrhythmias, positioning it as a promising player in the medical device sector.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Ekuore is a technology company based in Valencia, Spain, founded in 2012, that specializes in the design, development, and marketing of medical devices that integrate health services with mobile technologies. The company focuses on creating mHealth devices aimed at revolutionizing sanitary teleassistance, allowing for efficient and cost-effective monitoring and control of patients. Ekuore's flagship product is a digital electronic stethoscope designed to track and monitor patients' conditions, particularly in diagnosing cardiovascular diseases. This device compares physiological parameters against a comprehensive database to provide objective diagnoses, enabling hospitals to conduct secure digital consultations and enhance patient care.

Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

QMENTA is a software platform focused on imaging-based clinical studies, primarily aimed at enhancing the diagnosis and treatment of brain diseases. The company offers a cloud-based data management engine that integrates patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms. This platform allows healthcare professionals to compliantly collect, process, and analyze large-scale brain images and associated data efficiently. QMENTA's solutions encompass data management systems, clinical trials, neuroimaging disease packages, and neuro-data services, thereby facilitating improved medical imaging management and supporting clinical care and neuro research.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Laminar Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative medicines using a novel therapeutic approach known as Membrane Lipid Therapy (MLT). The company focuses on the rational design and initial clinical development of MLT-based drugs, aiming to create next-generation treatments that target membrane lipids. In addition to pharmaceuticals, Laminar Pharma also develops nutraceuticals and cosmetic products based on this unique therapeutic strategy, providing healthcare professionals with new options to address various medical needs.

Tractivus is a biotechnology company focused on addressing challenges in the field of biomedical devices. Emerging from research institutions IQS and IDIBELL, the company specializes in developing implantable medical devices designed to prevent bacterial colonization. Their product lineup includes phobostech, catheters, and tracheal stents. Tractivus employs a patented technology that creates thin nanocoatings on device surfaces, imparting bacteria-resistant properties. This innovation not only enhances the longevity of medical devices but also reduces associated costs and minimizes post-implantation complications, all while ensuring patient safety.

Rithmi is a privately held company focused on heart health and stroke prevention through innovative arrhythmia detection technologies. The company has developed a device that records data and detects arrhythmias in real time by measuring the intensity of light reflected on the skin's surface, creating a waveform of heart pulses. This technology offers a level of accuracy comparable to an electrocardiogram (ECG), making it a significant advancement in the diagnosis of atrial fibrillation. After successful pilot tests of its prototype, Rithmi is poised to expand into new markets in Europe, demonstrating strong potential for rapid growth and a commitment to enhancing patient care through its unique approach to Computational Predictive Care.

RheoDx is a developer of a diagnostic medical device focused on enhancing the quality of life for hematology patients. The company's innovative device measures the behavior of blood in motion, utilizing just a small drop of blood to detect changes in rheological properties. These changes can indicate abnormalities in red blood cell morphology and rigidity, which are linked to various diseases, including blood coagulation disorders, malignant homeopathies, malaria, and hereditary anemias. Designed for simplicity and portability, the device can be used at the point of care or in home settings, allowing patients to perform tests themselves. This approach not only facilitates timely monitoring but also aims to improve patient outcomes at competitive prices.

DERMA INNOVATE, S.L. is a Biotechnology Company, created and owned by Cannan research & Investment, focused on obtaining a series of advanced compounds in the area of skin and hair regeneration.

Fesia Technology specializes in developing advanced medical devices that utilize functional electrical stimulation for rehabilitation therapy aimed at individuals with neuromuscular diseases and injuries. The company has created an innovative system featuring a matrix-arranged electrode, which enhances the effectiveness of functional stimulation. One of its notable products, Fesia Walk, is designed specifically for patients experiencing foot drop and represents the first offering of this new generation of devices. Fesia's commitment lies in improving the quality of life for patients and providing healthcare professionals with cutting-edge technologies to support various stages of the rehabilitation process, particularly for those recovering from strokes and other central nervous system conditions.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Arcis Biotechnology Limited specializes in the development and commercialization of nucleic acid sample preparation solutions. The company offers a range of ready-to-use kits designed for the rapid extraction of nucleic acids from various biological samples, including whole blood, saliva, and cells from plants and animals. Their products, such as the Arcis Sample Prep Kit and the Arcis Blood Kit, enable users to obtain genetic material in less than three minutes without the need for laboratory equipment or extensive sample preparation. The technology facilitates the extraction of DNA and RNA from small sample volumes, with applications in point-of-care diagnostics, forensic analysis, and genomic research. Arcis Biotechnology provides its solutions through distributors in multiple countries, including the United Kingdom, India, and Belgium. Established in 2013 and based in Warrington, United Kingdom, the company was formerly known as Arcis Molecular Limited before rebranding in 2018.

Adan Medical Innovation, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2014. The company specializes in developing medical devices to assist with the management of anaphylaxis, particularly for individuals who require epinephrine. Its flagship product, Anapphylaxis, is a smart case for epinephrine auto-injectors that connects to a mobile application via Bluetooth. This device not only monitors the condition of the epinephrine but also alerts users if they forget their injector and activates a pre-defined action plan in case of an anaphylactic event, providing clear instructions for drug administration and notifying designated contacts with the user's location. Additionally, Adan Medical is working on WE SAVE, a smart box designed for public spaces that contains epinephrine auto-injectors, further enhancing the safety and management of severe allergic reactions.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed preclinical nonwoven nanofiber membranes that facilitate the controlled release of active agents, aimed specifically at the local treatment of unresectable tumors. Through extensive in vitro and in vivo characterization, Cebiotex provides innovative solutions to support medical professionals in addressing the challenges associated with treating difficult-to-reach cancer tumors.

Davalor Salud operates in the health sector, focusing on the development and commercialization of innovative hardware and software for visual health. The company provides diagnostic services for visual function and offers visual training solutions designed to enhance accessibility to functional visual health services. Utilizing advanced technology, Davalor Salud's devices autonomously measure vision and deliver visual training through engaging 3D video games. This approach specializes in the exploration, diagnosis, and therapy of various functional visual health issues, ultimately aiming to improve the quality of life for individuals facing such challenges.

MJN improves the quality of life of people suffering from epilepsy thanks to our wearable ear piece that performs an EEG of the patient. By applying AI algorithms, MJN-SERAS is able to interpret the brain signal, record epileptic seizures, objectively improve the medical monitoring and permanently assess the risk of suffering an epilepsy seizure

Biohope focuses on creating diagnostic and therapeutic solutions specifically for organ transplantation. The company has developed a system that aids in the immunological clinical management of kidney transplant patients. This system utilizes a patient's blood sample to tailor treatment with immunosuppressive drugs, allowing healthcare professionals to effectively manage autoimmune diseases such as arthritis and reduce the risk of organ rejection. Through its innovative approach, Biohope aims to enhance patient outcomes in the field of transplantation.

Vytrus Biotech SL is a company based in Barcelona, Spain, specializing in the development, production, and commercialization of active ingredients derived from plant stem cells. Founded in 2009 as a spin-off from the Universitat de Barcelona's Faculty of Pharmacy, the company leverages over 30 years of research in plant biotechnology to create high-value active ingredients for the cosmetics and pharmaceutical industries. Vytrus Biotech offers a range of products, including cosmetic formulations rich in cell factors, phyto peptidic fractions, dermatological solutions, and customized products. The company's portfolio features natural actives such as Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, and Qura Noni, emphasizing their commitment to harnessing the potential of plant-based ingredients for diverse applications.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company specializes in creating products that target harmful bacteria, including staphylococcus aureus, clostridium difficile, and streptococcus pyogenes. Absynth employs a unique platform to identify novel protein antigen targets that enhance the immune response. Its approach utilizes a dual-action mechanism, which combines direct antibacterial activity through antibody-mediated effects with the activation of classic immune functions to combat bacterial pathogens. This strategy aims to improve patient immunity and address significant health threats posed by these infections.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing novel therapies for inflammation and autoimmune diseases. Established in 2014, the company aims to modify a naturally occurring protein with significant immunoregulatory functions. Ducentis targets the CD200/CD200R axis, which delivers a deactivating signal to activated immune cells in both the innate and adaptive immune systems. Their potential therapeutic applications include addressing transplant rejection and treating various autoimmune and inflammatory diseases that affect the lungs, liver, kidneys, eyes, bones, and cartilage.

TBIOM biotechnological startup that aims to develop sustainable medical products and solutions to help large sectors of the population. TBIOM is working on the development of different electronic mhealth devices such as the control system for chronic alcoholism ETHAXIP (intra-oral device) or the DALVC system for performing continuous bladder washes in hospital centers. This last device is being developed jointly with Vecmedical and Vall d'Hebrón Hospital . In addition, TBIOM has developed and patented a new CPAP device for sleep apnea, portable, autonomous and mHealth , which also manages and encourages the health and care of people with this respiratory difficulty called Airmony.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed preclinical nonwoven nanofiber membranes that facilitate the controlled release of active agents, aimed specifically at the local treatment of unresectable tumors. Through extensive in vitro and in vivo characterization, Cebiotex provides innovative solutions to support medical professionals in addressing the challenges associated with treating difficult-to-reach cancer tumors.

The Pump it Nanotech S.L is a Start Up born from the Pump it project. This project was a response to the challenge presented by SENER, regarding the troublesome behaviour of bubbles in microfluidic devices in microgravity, during the 5th Ideas Generation Program: Aeroespacial Technologies from UAB (PRUAB).

Bioprognos is a spin-off from the Hospital Clínic of Barcelona focused on enhancing clinical outcomes and quality of life for cancer patients. The company specializes in developing innovative, non-invasive diagnostic solutions that are both accurate and cost-effective. Bioprognos offers test services aimed at the early detection and effective management of cancer by utilizing Multiple Biomarkers Disease Activity Algorithms (MBDAAs). These algorithms facilitate the qualitative detection of various neoplasia-associated biomarkers present in body fluids. Through their simple blood tests, Bioprognos provides essential information to patients and healthcare professionals, enabling informed decision-making regarding cancer and other related conditions.

Cebiotex specializes in manufacturing technology and contract research focused on drug delivery using electrospun nanofiber technology. The company has developed preclinical nonwoven nanofiber membranes that facilitate the controlled release of active agents, aimed specifically at the local treatment of unresectable tumors. Through extensive in vitro and in vivo characterization, Cebiotex provides innovative solutions to support medical professionals in addressing the challenges associated with treating difficult-to-reach cancer tumors.

Braingaze specializes in addressing cognitive disorders by utilizing a patented method that analyzes small involuntary eye movements to assess neural activity. Their technology leverages functional games to elicit these eye movements, with algorithms developed through Deep Learning to differentiate between real patient cases and control groups. The company focuses on early detection of conditions like Alzheimer's disease and ADHD, offering diagnostic tools and digital therapy solutions that have demonstrated more than a 50% reduction in symptoms. Braingaze's products are CE Mark certified as medical devices, ensuring compliance with health and safety regulations. With a commitment to improving mental health care, Braingaze is at the forefront of innovative solutions for cognitive disorders.

Capital Cell is a European equity crowdfunding platform based in Barcelona, Spain, that specializes in biotechnology and life sciences projects. Founded in 2014, the company serves as a meeting point for entrepreneurs and private investors, including venture capitalists and business angels, to facilitate funding for innovative medical science initiatives. By leveraging the power of the crowd, Capital Cell enables researchers and companies in the biotech sector to access a diverse pool of investment, thereby fostering the growth and development of cutting-edge solutions in healthcare.

QMENTA is a software platform focused on imaging-based clinical studies, primarily aimed at enhancing the diagnosis and treatment of brain diseases. The company offers a cloud-based data management engine that integrates patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms. This platform allows healthcare professionals to compliantly collect, process, and analyze large-scale brain images and associated data efficiently. QMENTA's solutions encompass data management systems, clinical trials, neuroimaging disease packages, and neuro-data services, thereby facilitating improved medical imaging management and supporting clinical care and neuro research.

ZeClinics is a biotechnology start-up that provides an outsourcing solution for safety and efficacy screenings of novel chemical compounds, utilizing zebrafish as a model organism. The company has developed a platform that tracks toxicity data and preserves embryos of marine species, primarily focusing on the use of zebrafish larvae for toxicology screening. This innovative approach enables biotechnologists to assess the toxicity of drugs and related protein molecules, facilitating accurate dosage recommendations and enhancing drug development processes. By leveraging the unique biological properties of zebrafish, ZeClinics aims to streamline the evaluation of new pharmaceuticals and contribute to advancements in the field of drug safety.

Developing a genetic test to help reduce the risk of hospital infections.